Human trials of COVID 19 drug EIDD-2801 to begin in a few weeks


After weeks of uncertainty and paranoia, finally a drug has been found that can potentially treat COVID19.  The Food and Drugs Administration (FDA) of USA is claiming to have done the trials on mice and has just got a go ahead to test this drug on affected humans now. Researchers at Emory University have arrived at this drug and have named it EIDD-2801.

What this antiviral drug has done in mice is that it has reduced the lung damage caused by the  virus SARS-CoV. The drug is deemed effective for cultured human lung cells with SARS-CoV-2 also. This is seen as relief drug in the disease and seems to be working against the entire Coronavirus family. Vaccines have not yet been developed for the disease. The danger of introducing vaccines quickly are that long term implications and side-effects of the vaccine would’t be known. It is still 12-18 months for any vaccine to arrive.

This novel drug under tests seems to be in the form of pill and need not be taken intravenously. The patients who are in the early stage of the disease will also benefit greatly. Professor Ralph Baric, of Department of Microbiology and Immunology stated that this new drug can not only be helpful in COVID 19 complications but also other associated complications of the virus.

Other works under research stage are reusing of old medicines like Hydroxychloroquine (HCQ) and Avigan. Another treatment under works is convalescent plasma therapy. The disadvantage of convalescent plasma therapy is that it needs heavy infrastructure. For now, and oral pill seems to be the most bankable option and EIDD-2801 seems to have brought a ray of hope in that direction. Pharma company Ridgeback Biotherapeutics has been contacted for these trials and later development of the drug.


A part-time pharmacist by profession, Aaron studied various advances of medicine for years. He also showed keen interest in reporting and understanding the new improvements in medicine technology. As an editor of Vegan Columnist, he keeps an eye on the news pieces for quality while jotting down some of the most interesting news from medicine sector.

Leave a Reply

Your email address will not be published. Required fields are marked *